(Press-News.org) Immunotherapy before surgery for patients with metastatic melanoma appears to be especially successful. Fifty-nine percent of patients responds so well to this therapy that adjuvant treatment is no longer needed, according to the results of the NADINA study that were published today.
The NADINA study, led by researchers from the Netherlands Cancer Institute, was named one of the eleven clinical studies with the biggest impact on health care in 2024 by Nature Medicine. The study now proves that this was not an empty claim, as shown by the results presented by medical oncologist and research leader Christian Blank today during ASCO 2024, the international congress of the American Society of Clinical Oncology in Chicago. The results have also been published in New England Journal of Medicine (NEJM).
Long lead-up
Standard treatment for patients with metastatic skin cancer (melanoma stage III) consists of the removal of the local lymph nodes, followed by a year of adjuvant treatment with immunotherapy or targeted therapy. “Despite that, we still see disease recurrence within three to five years in nearly half of these patients,” Blank explains. That’s why he setup the OpACIN trial ten years ago, in which immunotherapy before surgery (neoadjuvant immunotherapy) was compared to immunotherapy after surgery (adjuvant therapy). The study showed that neoadjuvant immunotherapy could induce a stronger and broader immune response against the tumor, at the cost of more side effects. Blank: “That’s why we initiated the OpACIN-neo trial, comparing three schedules with varying doses and eventually finding a safe and effective schedule. In the subsequent PRADO trial, we applied this optimal dose to 99 patients. The patients who responded well to the treatment were able to forgo surgery and adjuvant treatment.”
In 2022, Blank and his research group published the results of the PRADO study, in which 60 out of 99 patients with metastatic melanoma responded well to immunotherapy before surgery. “Conducting these studies eventually led to the design of the NADINA trial, the first phase 3 trial investigating neoadjuvant checkpoint inhibition for early stage melanoma,” Blank states.
High response rate
In the international investigator initiated NADINA trial, 423 patients were randomized to two groups: the first group received two immunotherapy treatments with ipilimumab and nivolumab, followed by surgery. The second group received standard treatment involving surgery followed by 12 rounds of immunotherapy with nivolumab. “In 59% of patients who had received immunotherapy before surgery, the tumor was nearly entirely or completely gone, which meant that they did not require additional treatment.” Even people who did not respond well to the therapy and had an unfavorable prognosis benefited from the therapy: they were able to start adjuvant treatment with immunotherapy or targeted therapy after surgery.
Effective and cost-efficient
The effects of the treatment become apparent quickly. After one year, almost 84% of patients who had received neoadjuvant treatment were still tumor-free, compared to 57% of the group receiving standard treatment. Blank: “Patients whose tumors were nearly entirely or completely gone, saw even better results; 95% remained tumor-free, after only six months of treatment.” 76% of patients whose tumors were only partially gone were still tumor-free one year after the start of their treatment, compared to 57% of patients who did not respond well to neoadjuvant therapy. These two patient groups received additional adjuvant treatment after their neoadjuvant treatment and surgery. In three years, the researchers expect to know whether this positive trend continues and could improve survivorship. The next challenges in this field will be to improve treatment outcomes of patients who responded less favorably.
Besides a greater chance of tumor-free survival, most patients were able to cut down their treatment time to only six weeks. Blank: “Treatment is a lot cheaper – €16,000 instead of €68,000, which would free up about 30 to 40 million euros in the Netherlands, and could reach a billion euros worldwide.”
The treatment still needs to be registered and approved in the Netherlands to qualify for health care insurance coverage. That’s why it will not be immediately available. Blank: “We are talking with various public authorities to ensure that the treatment can eventually receive coverage.”
Personalized medicine
There are many studies looking into neoadjuvant treatments for various cancer types, including lung cancer, bladder cancer, and breast cancer. “These trials often combine a neoadjuvant approach with standard adjuvant treatment after surgery, instead of adapting treatment to the response to the neoadjuvant part,” Blank explains. “The NADINA trial is the very first trial within the oncological field that researched a purely immune-therapeutic and personalized treatment. Eventually we aspire to be able to provide personalized immunotherapy by reading out the tumor RNA in every individual patient, and providing a treatment that we know works best based on the results.”
END
Neoadjuvant Immunotherapy for early stage melanoma shows positive results
2024-06-02
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
CDC reports its decade-long efforts in standardizing vitamin D tests
2024-06-02
BOSTON—Vitamin D tests certified by the U.S. Centers for Disease Control and Prevention (CDC) Clinical Standardization Programs (CSP) are well calibrated overall, according to a new study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass. However, the researchers found some inaccuracies among the assays studied.
The blood tests show an “appropriate” level of analytical accuracy, said the study’s lead researcher, Otoe Sugahara, manager of the CDC Vitamin D Standardization-Certification Program (VDSCP) in Atlanta, Ga.
Analytical accuracy is the test’s ability to correctly analyze vitamin D in this ...
Persons of nonbinary gender may desire lower-dose testosterone treatment than guidelines recommend
2024-06-02
BOSTON—Among transgender and gender-diverse adults whose gender identity is nonbinary—not exclusively male or female—and who choose low-dose hormone treatment, most prefer to continue testosterone therapy at lower-than-recommended doses after at least six months of treatment, a new study finds. The study will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Current guidelines for initiation of testosterone for gender affirmation assume that transgender and gender-diverse, or trans, individuals desire both rapid and complete masculinization,” ...
High insulin levels contribute to worse outcomes for Black women with aggressive form of breast cancer
2024-06-02
BOSTON—High insulin levels contribute to worse outcomes for Black women compared to white women who have an aggressive form of breast cancer called triple-negative breast cancer, according to a study presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Triple-negative breast cancer accounts for about 10-15% of all breast cancers. The term triple-negative breast cancer refers to the fact that the cancer cells do not have estrogen or progesterone receptors and do not make any or too much of the protein called HER2. The cells test ‘negative’ on all 3 tests. Triple-negative breast ...
Stress from living in violent neighborhoods tied to aggressive lung cancer in Black men
2024-06-02
BOSTON—Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“This research uncovers a previously unknown link between exposure to neighborhood violence, GR and lung tumor aggressiveness that can help us understand and fix the lung cancer health disparity seen in Black men” said Hannah Heath, B.S., a graduate research assistant ...
Thyroid eye disease patients report maintained improvement 2 years after teprotumumab infusions
2024-06-02
BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass., and published in the journal Thyroid.
“Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated. This is the case for many autoimmune diseases,” said George Kahaly, M.D., Ph.D., professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. “Given the enduring nature ...
More women report hip fractures earlier in life
2024-06-02
BOSTON—Older women with low bone density are more likely to experience their first hip fracture in their 60s compared to older ages, according to research being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
“Older women experience an increased risk of fragility hip fractures. These are hip fractures with minimal trauma or due to a fall from a standing height, and they are often deadly and disabling,” said Avica Atri, M.D., an Internal Medicine resident physician at Jefferson Einstein Hospital in Philadelphia, Pa. “As the population over 60 swells in the United States, a large proportion of women will be ...
Cutting-edge robotics: Introducing the hybrid-driven origami gripper
2024-06-02
In an impressive leap forward for robotics technology, researchers from Shanghai Jiao Tong University have unveiled a novel hybrid-driven origami gripper, designed to tackle the challenge of grasping and manipulating objects with unprecedented versatility and precision. This innovative device, highlighted in a recent study published in Cyborg Bionic Systems, promises to reshape the capabilities of robotic systems in industries ranging from manufacturing to healthcare.
The newly developed gripper utilizes a combination of pneumatic and cable-driven mechanisms to control an origami-inspired structure, allowing for adjustable finger stiffness and variable finger lengths. This sophisticated ...
The future of drug testing: Vascularized organ-on-a-chip technologies
2024-06-02
In an era marked by rapid technological advancement in biomedical engineering, a groundbreaking development is set to revolutionize our approach to drug testing and disease modeling. Researchers from Shanghai University and the University of California Los Angeles have made significant strides in the field of in vitro vascularized organ-on-a-chip systems, offering a promising alternative to traditional methods that rely heavily on animal testing and simplistic two-dimensional cell cultures.
The organ-on-a-chip technology mimics human organs on a microscale by cultivating cells in a controlled microenvironment that simulates the 3D structure and physiological ...
New male birth control gel takes effect sooner than similar contraceptive methods
2024-06-02
BOSTON—A novel male contraceptive gel combining two hormones, segesterone acetate (named Nestorone) and testosterone, suppresses sperm production faster than similar experimental hormone-based methods for male birth control, according to a new study.
Results from an ongoing multicenter phase 2b clinical trial will be presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston.
“The development of a safe, highly effective and reliably reversible contraceptive method for ...
Study finds potentially treatable factors to improve symptoms in men stopping illicit steroids
2024-06-02
BOSTON—Men who illicitly used steroids to boost muscle size and physical performance and have stopped in the past year have impaired sexual function compared with men currently using steroids, according to a study being presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
Having a psychiatric diagnosis and stopping steroids was associated with greater impairment in sexual function, the researchers found.
“It is important to recognize the symptoms that men experience within the first year of stopping ...